Publications by authors named "H Takabatake"
Background: To identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC).
Methods: In total, 188 patients with HCC, who received atezolizumab plus bevacizumab combination therapy as the first-line chemotherapy, were studied. Patients who achieved complete response (CR) with systemic chemotherapy alone were excluded.
Article Synopsis
- The study introduces a new method for large-factor super-resolution (SR) in medical imaging called SGSR, which is designed specifically for dealing with registered low-resolution (LR) and high-resolution (HR) image pairs that may have registration errors.
- SGSR utilizes an innovative approach with style-subnets-assisted generative latent bank (S-GLB) and a novel inter-uncertainty loss, optimizing the generation of realistic images by leveraging pre-existing image models and additional spatial information.
- Experimental results demonstrate that SGSR significantly surpasses previous state-of-the-art SR methods in both quality and accuracy, leading to improved reconstructions in medical images and aiding in better clinical outcomes.
Background/aim: Immunotherapy using immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Although several ICI options are available, the treatment regimen for NSCLC with large size tumors (large NSCLC) is controversial and the efficacy of anti-CTLA-4 antibody is unclear. This study thus investigated potential biomarkers for CTLA-4 blockade.
View Article and Find Full Text PDFBackground And Aims: The IMbrave 150 trial revealed the usefulness of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma (HCC), making it now considered the first-line systemic chemotherapy agent for HCC. The present study investigated factors associated with early tumor progression of atezolizumab plus bevacizumab in patients with advanced HCC in real-world clinical practice.
Methods: A total of 184 HCC patients who received atezolizumab plus bevacizumab therapy were studied.